Inventiva (IVA) - Pendapatan reged perusahaan

Lambang korporat lan logo Inventiva (IVA)

Inventiva S.A. (IVA) is seeking a global partner to bring its drugs to market while avoiding mergers. High biotech costs and stringent FDA oversight create significant barriers. The company's sales time series on the GURU.Markets platform demonstrates revenue dynamics, where the 0.00 level reflects the current magnitude. The firm is developing oral medications, focusing on the therapy of fibrosis and metabolic liver disorders.

Inventiva Corp - Dodolan perusahaan IVA (periode 04.07.2022 - 13.11.2026)

Rincian analitis perusahaan Inventiva S.A.

- rega saham lan prakiraan rega para ahli:
Bagan owah-owahan rega Inventiva Corp|IVA - Prakiraan konsensus analis
- indikator kapitalisasi pasar:
Kapitalisasi pasar Inventiva S.A.|IVA - Nilai Total Perusahaan
- data kapitalisasi buku:
Ekuitas saben Saham Inventiva|IVA - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku inventivapharma.com|IVA - Total Aset Perusahaan
- data liabilitas lan likuiditas perusahaan:
Utang marang Modal Inventiva S.A.|IVA - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal Inventiva SA|IVA - Gunggung utang perusahaan|Utang marang modal buku Inventiva S.A.|IVA - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Inventiva|Likuiditas cepet inventivapharma.com
- rincian asil keuangan lan kelipatan valuasi:
IVA - Bathi resik|Proyeksi bathi mangsa ngarep Inventiva S.A.|IVA - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi inventivapharma.com|IVA - Rasio rega marang bathi tumrap wutah|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Inventiva S.A.|IVA - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan Inventiva|IVA - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan inventivapharma.com|IVA - Wutah bathi resik saben saham ing taun iki|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Inventiva S.A.
- rincian pendapatan lan dodolan emiten:
IVA - Pendapatan lan volume dodolan|Dodolan mangsa ngarep perusahaan Inventiva Corp|IVA - Kapitalisasi marang pendapatan|Rasio rega marang prakiraan pendapatan Inventiva S.A.
Analisis umum perusahaan:Inventiva Corp, IVA
Produk asli Inventiva Corp

Inventiva S.A. is optimizing its biotechnological developments through ESG standards by minimizing laboratory waste. The company's current sales level reflects the pace of its operational business expansion in the US market. This indicator measures real revenue volume, allowing for an assessment of the issuer's market share retention. Analysis of the chart's dynamics reveals a risk of price stagnation should revenue growth slow. High turnover does not preclude volatility in the event of a shortage of market liquidity.

Pesaing wigati

ARWR: Pendapatan dodolan perusahaan|Pendapatan lan volume dodolan MIRM|Pendapatan reged perusahaan Dynavax Technologies Corporation|Pendapatan perusahaan Arbutus Biopharma Corporation ABUS|GYRE: Volume dodolan perusahaan|ASMB: Dodolan perusahaan|GALT: Pendapatan perusahaan|GNFT: Pendapatan lan volume dodolan|Total pendapatan perusahaan DURECT (DRRX)|Pendapatan perusahaan Aligos Therapeutics Inc.|Volume dodolan perusahaan BIVI (BioVie Pharma)|Dodolan perusahaan GLMD (Galmed Pharmaceuticals)|Total dodolan perusahaan NDRA|Pendapatan lan volume dodolan HEPA (Hepion Pharmaceuticals, Inc.)